Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TriNet Group

Tractor Supply

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Advanced Drainage Systems

Economists are starting to think a W-Shaped recovery is more likely to happen than a “V.” We lean on deep learning algorithms and AI tech to generate the top stocks to short, and these are our latest.

Best Stocks To Buy As S&P 500 Paces To End Week With Modest Gains

INDIANAPOLIS, July 17, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key.

Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly's valuation is stretched and financial leverage is high, both risks if operating results falter.

Eli Lilly: Upside Momentum Fading Fast

INDIANAPOLIS, July 15, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable September 10, 2020, to shareholders of record at the close...

Lilly Declares Third-Quarter 2020 Dividend

Gilead Sciences

Johnson & Johnson

Moderna

Pfizer

After a few years hanging out quietly on the sidelines, the Health Care sector roared back to prominence this year as COVID-19 ravaged the globe. Suddenly, vaccines and antibodies catapulted into the headlines, drawing attention to biotech and pharma amid a race to treat or prevent the virus.

GILDing” The Lilly: Vaccines, Treatments For Virus In Spotlight Ahead Of Health Care Q2 Earnings

BJ`s Wholesale Club Holdings Inc

Everbridge

Kroger

Sprouts Farmers Markets

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

5 Low-Beta Stocks to Beat Coronavirus-Induced Volatility

AbbVie

Horizon Pharma

Novo Nordisk

Dr. Reddy's Labs

United Therapeutics

Zoetis

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeared first on InvestorPlace.

The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase

Roche Holding AG

Blueprint Medicines stock popped Tuesday on a $775 million deal with pharma giant Roche to sell a cancer treatment, pralsetinib. The drug targets abnormalities in the RET gene.

Could A $775 Million Roche-Blueprint Deal Unseat Eli Lilly In Cancer?

Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.

FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus

Abbott Labs

Merck

Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.

Why Big Pharma's $1 Billion Bet to Prevent a Bacterial Pandemic Matters for You

AstraZeneca

These healthcare leaders give you a relatively low-risk way to invest in the fight against COVID-19.

Have $5,000? 3 Coronavirus Stocks You Can Buy in July Without Losing Any Sleep

Is  (LLY) Outperforming Other Medical Stocks This Year?

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

A new $1 billion fund backed by 20 drugmakers including Eli Lilly, Merck and Pfizer is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday.

New $1 billion fund aims to steer antibiotic companies in a tough market

Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.

Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis

Dynavax Technologies

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

Both of these stocks have strong growth potential.

Better Coronavirus Stock: Eli Lilly or AbbVie?

Amazon

NVIDIA

T-Mobile US

Tesla

A handful of corporate behemoths has skyrocketed YTD. Some of these stocks carry a favorable Zacks Rank and have rallied more than 20% YTD.

Pandemic Fails to Deter YTD Rally of These Top 5 US Behemoths

These two healthcare behemoths have something to offer most investors.

Better Buy: Eli Lilly vs. Johnson & Johnson

Despite a 37% rise since the March 23 lows of this year, at the current price of around $163 per share we believe Eli Lilly’s stock has more room for growth. Eli Lilly stock has rallied from $119 to $163 off the recent bottom, in-line with the S&P which moved 36%.

Is There More Upside For Eli Lilly Stock At $160?

Amgen

Bristol-Myers

Novartis

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Axsome Therapeutics

Biogen

Demand for Alzheimer's medication is expected to grow as the population of older adults rises.

Should You Buy These 3 Stocks Tackling Alzheimer's Disease?

These are two worthy contenders for your investment portfolio.

2 Top Diabetes Stocks to Buy Right Now

These drugmakers' businesses shouldn't be significantly impacted by an economic downturn.

3 Top Pharma Stocks to Buy in a Recession

Eli Lilly’s stock has rallied 35% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $160 after falling to a low of $119 in late March as a rapid increase in the number Covid-19 cases outside China resulted in heightened fears of an imminent global economic downturn.

What’s Next For Eli Lilly After 35% Rally?

In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.

News for Eli Lilly Stock (LLY)